CompletedNot applicableNCT04872738
Official study title

Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment

Study summary

This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery. Lymph node swelling is a known and common side effect of both the Moderna and Pfizer COVID-19 vaccines. This is the body's normal reaction to the vaccine. It is worrisome that lymph node swelling after the vaccine mimics that found in breast cancer which has spread to the lymph nodes. This side effect will cause worry and anxiety amongst patients as a result. For patients who have had lymph node removal (axillary lymph node dissection or sentinel lymph node biopsy) and are at risk of lymphedema, the investigators are concerned that the lymph node swelling may tax the lymphatic system and incite lymphedema in those at risk or worsen it in those with BCRL. Fear of lymphedema is high in this population and the investigators need to better understand what risk, if any, lymph node swelling after the COVID-19 vaccine imparts to BCRL risk.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSurvey

The study team can explain what participation involves.

Who it may be forBreast Cancer Related Lymphedema · Covid19

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 6, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Massachusetts General Hospital

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Massachusetts General Hospital
Interventions being studied
Other: Survey
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Female patients who are
  • ≥18 years of age and have a
  • History of breast cancer For the MGH site, patients must have
  • Received some breast cancer treatment at MGH or its affiliates
  • Received perometry measurements to measure arm volume at MGH
Reasons someone may not be able to joinExclusion criteria

None

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Massachusetts General Hospital Cancer CenterBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 6, 2026. Always confirm current availability with the study team.

View original record ↗